Novartis announced Friday that an experimental cardiovascular drug failed in a pivotal study. The company described the failure as a major setback.
Failed pivotal studies can delay or prevent drug approvals and represent significant financial and strategic losses for pharmaceutical companies.
No published comments yet.
Quarterly reported positions. These filings can arrive up to 45 days after quarter-end and are not real-time trades.
Institutional ownership: 6.82%
| Owner | Activity | Change | Shares held | Value (thousands) | Reported |
|---|---|---|---|---|---|
| Fisher Asset Management, Llc | Buy | 1,637,629 (11.794%) | 15,523,378 | $2,425,838 | 6/30/2026 |
| Morgan Stanley | Buy | 199,790 (2.343%) | 8,726,827 | $1,363,741 | 6/30/2026 |
| Dimensional Fund Advisors Lp | Buy | 7,470 (0.092%) | 8,117,586 | $1,268,535 | 6/30/2026 |
Source: Nasdaq
Open short positions reported twice monthly; this is not daily short-sale volume.
Recent reported earnings per share compared with the analyst consensus available from Nasdaq.
| Primecap Management Co/Ca/ |
| Sell |
| -975,230 (-12.887%) |
| 6,592,124 |
| $1,030,151 |
| 6/30/2026 |
| Loomis Sayles & Co L P | Sell | -186,791 (-3.442%) | 5,239,309 | $818,747 | 6/30/2026 |
| Bank Of America Corp /De/ | Sell | -52,856 (-1.065%) | 4,909,938 | $767,276 | 6/30/2026 |
| Franklin Templeton Inc | Sell | -158,663 (-4.653%) | 3,251,281 | $508,078 | 6/30/2026 |
| Blackrock, Inc. | Buy | 98,228 (3.33%) | 3,047,988 | $476,309 | 6/30/2026 |
| Goldman Sachs Group Inc | Sell | -3,545,603 (-54.332%) | 2,980,168 | $465,711 | 6/30/2026 |
| Northern Trust Corp | Buy | 6,517 (0.234%) | 2,792,745 | $436,422 | 6/30/2026 |
| Natixis Advisors, Llc | Buy | 150,371 (6.725%) | 2,386,527 | $372,943 | 6/30/2026 |
| Envestnet Asset Management Inc | Buy | 19,595 (0.848%) | 2,330,979 | $364,262 | 6/30/2026 |
| Settlement date | Short interest | Avg. daily volume | Change vs. previous report | Days to cover |
|---|---|---|---|---|
| Sep 30, 2026 | 5,624,031 | 1,921,289 | +8.24% | 2.93 |
| Sep 15, 2026 | 5,195,725 | 3,525,832 | -7.63% | 1.47 |
| Aug 31, 2026 | 5,625,158 | 1,333,406 | +12.65% | 4.22 |
| Aug 14, 2026 | 4,993,689 | 1,455,729 | -4.71% | 3.43 |
| Jul 31, 2026 | 5,240,722 | 1,951,524 | -8.28% | 2.69 |
| Jul 15, 2026 | 5,713,789 | 1,590,064 | +6.69% | 3.59 |
| Jun 30, 2026 | 5,355,498 | 2,749,767 | +2.07% | 1.95 |
| Jun 15, 2026 | 5,246,790 | 2,051,091 | +15.48% | 2.56 |
Source: FINRA Consolidated Short Interest
| Fiscal quarter | Reported | EPS | Consensus | Surprise |
|---|---|---|---|---|
| Jun 2026 | Jul 21, 2026 | 2.41 | 2.2 | +9.55% |
| Mar 2026 | Apr 28, 2026 | 1.99 | 2.11 | -5.69% |
| Dec 2025 | Feb 4, 2026 | 2.03 | 1.99 | +2.01% |
| Sep 2025 | Oct 28, 2025 | 2.25 | 2.26 | -0.44% |
Source: Nasdaq
